



Journal of Home Economics

Volume 25, Number (1), 2015

<http://homeEcon.menofia.edu.eg>

**Journal of Home
Economics**

ISSN 1110-2578

Effect of Anemia on the Treatment of Obesity

Adel A. AbdEloaty , Amani R. Imam

Nutrition and Food Science Department, Faculty of Home Economics, Minufiya University, Egypt.

Abstract: The present study was carried out to investigate the effect of iron supplement (IS) and high iron diet (HID) on obese anemic women. The study included 120 obese anemic women ($MBI \geq 30$) aged 30 to 50 years followed in obesity and slim clinic in Cairo, Egypt for 12 weeks. Their diet was modified to provide 1250–1350 kcal. The patients were divided into 3 groups ($n=40$) as follows: Group1 was taken a normal diet program; Group2 was taken iron supplement (IS) (Ferro Sanol Duodenal[®] capsule 50 mg) with normal diet program and Group3 was taken a high iron diet program (HID). The results showed significantly decreased of weight in IS group (74.43kg) compared with group 1 (80.01 kg) and HID group (79.47 kg). Similar findings were found in BMI. Waist circumference (WC) of IS group decreased significantly (95.02cm) compared with group1 (103.35 cm). Also the WC of group 3 (HID) decreased significantly (99.75cm). Hemoglobin (Hb) level increased significantly in IS group (13.98g/dl) compared with group1 (10.78g/dl) and HID group (11.54g/dl). The results of red blood cells RBCs indicated significantly increased in IS group (4.81mm^3) compared with group 1 (3.14mm^3) and HID group (3.58mm^3). In conclusion the results of this study show association of overweight and obesity with iron deficiency. This study suggests that the treatment of anemia is important for the treatment of overweight and obesity.

Key words: Iron deficiency, Anemia, Obesity, Hepcidin

Introduction

Obesity is a disease defined by an excess accumulation of body fat to the extent that health is adversely affected (WHO, 2000). Within only a few decades, obesity has become a global public health concern

(**Ogden et al., 2006**). The obesity epidemic is not limited to certain societies. The prevalence of obesity is increasing in all regions of the world (**WHO, 2000**). In 2005, an estimated 400 million adults worldwide were obese (**WHO, 2006**). The recent annual report from the International Association for the Study of Obesity documented approximately 1.5 billion of adults that are overweight, of whom around 525 million are clinically obese (**Abu-Farha et al., 2013**).

By 2010 an estimated one in seven children in the Americas and one in ten in the Eastern Mediterranean and European regions are predicted to be obese (**Wang and Lobstein, 2006**). In very recent report about the association between socioeconomic status (SES) and overweight or obesity in Cairo, **Mowafiet et al., (2014)**, analyzed the data which were taken from the 2007 Cairo Urban Inequity Study which collected information on 3993 individuals from 50 neighborhoods in the Cairo Governorate. Five different measures of SES were utilized—education, household expenditures, household assets, subjective wealth, and father's education. No significant associations were found between most measures of SES and overweight/obesity in this population. Overweight and obesity are prevalent across the SES spectrum. The global epidemic of obesity will continue to worsen. The public health implications of the obesity epidemic are staggering; obesity is associated with increased mortality from cardiovascular disease, diabetes, kidney disease, and some cancers (**Flegalet et al., 2007**).

Anemia has been associated with obesity and increased BMI (**Bentley and Griffiths, 2003; Nead et al. 2004; Batista et al., 2008**). According to WHO 1.3–2.15 billion people are anemic all over the world and more than 90% are living in the developing countries. Apart from developing countries, Middle East and North African countries also share the health problem of anemia (**Sultan, 2007 and Hanafiet al., 2013**).

The first reports of a potential connection between iron status and obesity appeared over 40 years ago, when **Wenzel et al., (1962)**, unexpectedly found a significantly lower mean serum iron concentration in obese compared with non-obese adolescents. Very few studies pursued the reported connection between iron status and obesity until recently, when a series of investigations described an increased prevalence of iron deficiency in overweight and obese populations. The first of these, a cross-sectional study published in 2003, described a greater prevalence of iron deficiency, as indicated by serum iron levels <8 mmol/L, in overweight and obese children and adolescents **Pinhas-Hamielet et al., (2003)**.

Menzieet al., (2008), found significantly lower levels of serum iron and transferrin saturation (the ratio of serum iron to total iron

binding capacity) in obese as compared to non-obese adult volunteers, and fat mass was shown to be a significant negative predictor of serum iron concentration. Collectively, these reports suggest that excess adiposity may negatively affect iron status. If overweight and obese individuals are at greater risk for reduced iron absorption and iron deficiency, what is the mechanistic link between body fat and iron homeostasis? A number of hypotheses have been proposed, including increased plasma volume in the obese, the consumption of energy-dense, nutrient-poor foods (Pinhas-Hamielec *et al.*, 2003), and chronic inflammation in response to excess adiposity (Yanoff *et al.*, 2007). Few of these hypotheses have been explored in detail. Unfortunately, no available study link between obesity and iron status in Egypt. The present study aimed mainly to determine iron status of obese women and its effect on obesity treatment.

Subjects and Methods

Subjects

The present study was done on a group of female patients between 30 and 50 years old suffering from anemia and obesity (BMI higher than 30 kg/m²). They were selected among those attending the obesity and slim out patient's clinic, Cairo, Egypt and were agreeing to involve in this study. 120 obese anemic women of the total 150 cases had continued in the program regularly until the end. The patients were randomized either to a control group, Iron supplement (IS), and High Iron diet (HID) all with a caloric content of 1250-1350 kcal. No information was given to change the level of physical activity of the participants.

Iron supplement

Ferro Sanol Duodenal[®] capsule each capsules contains the (equivalent to 50 mg Fe²⁺) in form of ferrous²-glycine-sulphate complex. Patients were taken one capsule a day of Ferro Sanol Duodenal(50 mg).

Design of the study:

The patients were randomized into 3 groups 40 patients in each group as following:

Group1: control was taken a normal diet program.

Group2: was taken iron supplement (IS) (Ferro Sanol Duodenal[®] capsule 50 mg) with normal diet program.

Group3: was taken a high iron diet program (HID).

Nutritional education brochures about obesity and anemia were given to each patient. The Anthropometric measurement Weight, height,

body mass index, Waist Circumference and Hip Circumference and Waist to Hip Ratio (WHR) were recorded for each case weekly. Fasting blood samples were obtained from each patient. The blood samples were divided into two parts; the 1st part was collected into heparinized tubeto measure Automated Complete blood count (CBC). The 2nd part was centrifuged at 3500 rpm for 15 min to obtain serum to measure lipid profile. Serum total cholesterol level was assayed by the method of **Naito, (1984)**. The serum level of triglyceride was determined by **Fossati and Prencipe, (1982)**. Serum HDL-c was determined according to **Grove, (1979)**. The low density lipoprotein (LDL) and very low density lipoprotein (VLDL) was calculated using the formula of **Friedewald et al., (1972)**. Free T4 (Thyroxine) according to **Beck-Peccoz et al., (1984)**. Thyroid Stimulating Hormone (TSH) according to the method of **Uotila et al., (1981)**.

Results

The results of weight of obese anemic women showed decreased significantly of group 2 (IS) to be 74.43 ± 10.91 kg compared with group 1 which was 80.01 ± 11.87 kg; while the mean value of weight of group 3 (HID) showed not significant compared with group 1. Similar findings were found in BMI. The results of waist circumference (WC) of obese anemic women showed decreased significantly in group 2 after the study to be 95.02 ± 6.86 cm compared with group 1 which was 103.35 ± 6.81 cm. Also the WC of group 3 (HID) was decreased significantly to be 99.75 ± 8.13 cm compared with group 1. With regarding of hip circumference (HC), the mean value of HC of group 2 (IS) showed decreased significantly after the study compared with HC of group 1 (control); whereas the mean value of HC of group 3 (HID) showed not significant with control group. The results indicated that the mean value of WHR of group 2 (IS) at the end of the study showed decreased significantly compared with group 1; while the mean value of WHR of group 3 (HID) showed non-significant difference compared with group 1 (**Table 1**).

The results of serum total cholesterol indicated that decreased level of group 1 to be 144.70 ± 26.67 mg/dl. However, the level of serum total cholesterol of group 2 (IS) was decreased significantly to 147.20 ± 25.98 mg/dl; while the level of serum cholesterol of group 3 (HID) increased to be 168.03 ± 19.26 mg/dl. Similar findings were recorded in the level of serum triglyceride (TC) that indicates lower levels in group 1 (not treated) and group 2 (IS). But the level of triglyceride of group 3 was significantly higher compared with groups 1 and 2. The level of serum high density lipoprotein HDL recorded

significantly higher in patient of group 2 (IS) compared with control group; whereas the level of HDL in group 3 (HID) was decreased significantly compared with group 1 (control). The result of serum low density lipoprotein (LDL) showed decreased significantly in group 2 (IS) compared with group 1 (not treated). However significant higher in serum LDL level was recorded in group 3 (HID). Very low density lipoprotein (VLDL) level showed decreased level in group 2 (IS); while the level of VLDL of group 3 was significantly higher compared with groups 1 (**Table 2**).

The level of serum thyroid stimulating hormone (TSH) showed slightly increased in groups 1 and 2 compared with the levels of at the beginning of the study; while group 3 (HID) showed slightly decreased compared with group 1 and 2. The results of serum T4 level of group 1 (control) was decreased to be 1.36 ± 0.30 $\mu\text{IU/mL}$; while the results showed slightly increased in groups 2 and 3 (**Table 3**).

The results of hemoglobin indicated that significant improvement in hemoglobin (Hb) level in group 2 (IS) from 10.55 ± 1.72 g/dl to 13.98 ± 2.76 g/dl compared with group 1 (control). However the level of hemoglobin of group 3 increased slightly to 11.54 ± 1.88 g/dl compared with group 1. The results of red blood cells RBCs indicated significantly increased in group 2 (IS) to be $4.81 \pm 0.50 \text{mm}^3$ compared with group 1 which showed slightly decreased to be $3.14 \pm 0.42 \text{mm}^3$; also the level of RBCs of group 3 was increased to be $3.58 \pm 0.25 \text{mm}^3$ after the study. The results of hematocrit of group 2 (IS) showed significantly increased after of the study to be $49.13 \pm 2.19\%$ compared with group 1 which was $40.37 \pm 2.94\%$ to be $40.95 \pm 3.23\%$; while the level of hematocrit of group 3 (HID) increased after of the study to be $42.55 \pm 4.03\%$ (**Table 4**).

With regarding to the results of MCH, the results showed significant improvement in group 2 (IS) to be $28.62 \pm 1.48 \text{g/dL}$ compared with group 1 (not treated) $28.10 \pm 1.88 \text{g/dL}$; also the result of group 3 (HID) showed increased to be $29.77 \pm 1.47 \text{g/dL}$. The result of MCV of group 2 (IS) showed increased significantly compared with group 1. However the results of group 3 (HID) showed increased from to be $81.75 \pm 4.75 \text{fL}$ at the end of the study. The result of platelets of group 2 (IS) showed significantly increased at the end of study to be $285.50 \pm 58.14 \text{mm}^3$ compared with group 1 which increased to be 266.67 ± 55.24 ; also the platelets of group 3 (HID) was increased to be $268.10 \pm 46.21 \text{mm}^3$ (**Table 4**).

Table (1): Effect of effect of iron supplement (IS) and high iron diet (HID) on anthropometric measurements of obese anemic women

	Group 1 (not treated)		Group2 (Iron Supplement)		Group3 (high iron diet)	
	Before	After	Before	After	Before	After
Weight (kg)	85.81± 10.61 ^a	80.01± 11.87 ^a	88.50± 11.11 ^a	74.43± 10.91 ^b	87.92± 13.53 ^a	79.47± 10.36 ^a
BMI (kg/m²)	33.16± 3.14 ^a	31.03± 3.42 ^a	33.65± 4.06 ^a	28.29± 3.51 ^b	33.45± 4.30 ^a	30.38± 3.79 ^a
WC (cm)	108.00± 7.91 ^{ab}	103.35± 6.81 ^a	109.97± 8.43 ^a	95.02± 6.86 ^c	104.80± 9.65 ^b	99.75± 8.13 ^b
HC (cm)	109.29± 7.59 ^a	105.90± 6.81 ^a	108.20± 5.90 ^a	100.55± 5.39 ^b	106.45± 6.01 ^a	103.20± 5.06 ^{ab}
WHR	0.988± 0.052 ^a	0.975± 0.048 ^a	0.952± 0.054 ^a	0.921± 0.052 ^b	0.984± 0.080 ^a	0.966± 0.061 ^a

*Values are means ± SD

** The mean difference is significant at the 0.05 level.

Table (2): Effect of iron supplement (IS) and high iron diet (HID) on serum total cholesterol (TC), triglyceride (TG), HDL-C, LDL-C and VLDL of obese anemic women.

	Group 1 (not treated)		Group2 (Iron Drug S)		Group3 (Iron Natural S)	
	Before	After	Before	After	Before	After
TC (mg/dl)	152.35± 34.21 ^b	144.70± 26.67 ^b	168.27± 30.70 ^a	147.20± 25.98 ^b	164.32± 23.20 ^{ab}	168.03± 19.26 ^a
TG (mg/dl)	128.62± 31.07 ^b	121.60± 24.97 ^b	144.57± 26.55 ^a	125.82± 21.63 ^b	138.05± 26.38 ^{ab}	147.55± 24.18 ^a
HDL (mg/dl)	54.40± 10.09 ^b	56.60± 9.31 ^b	46.54± 10.66 ^c	63.86± 19.91 ^a	59.95± 9.20 ^a	51.25± 7.51 ^c
LDL (mg/dl)	72.23± 31.99 ^b	63.76± 22.96 ^b	92.82± 32.22 ^a	58.18± 28.13 ^c	76.77± 24.30 ^b	87.27± 15.74 ^a
VLDL (mg/dl)	25.72± 6.21 ^b	24.34± 4.93 ^b	28.91± 6.16 ^a	25.16± 4.35 ^b	27.61± 5.10 ^{ab}	29.51± 5.21 ^a

*Values are means ± SD

**The mean difference is significant at the 0.05 level.

Table (3): Effect of iron supplement (IS) and high iron diet (HID) on serum thyroid stimulating hormone (TSH) and free thyroxine (T4) of obese anemic women.

	Group 1 (not treated)		Group2 (Iron Drug S)		Group3 (Iron Natural S)	
	Before	After	Before	After	Before	After
TSH (ng/dL)	2.38± 0.89 ^c	2.39± 0.90 ^b	2.77± 0.70 ^b	2.79± 0.73 ^a	3.10± 0.56 ^a	3.04± 0.54 ^a
T4 (µIU/mL)	1.38± 0.32 ^a	1.36± 0.30 ^{ab}	1.46± 0.42 ^a	1.47± 0.41 ^a	1.23± 0.19 ^b	1.27± 0.17 ^b

*Values are means ± SD

** The mean difference is significant at the 0.05 level.

Table (4): Effect of iron supplement (IS) and high iron diet (HID) on complete blood count (CBC) of obese anemic women.

	Group 1 (not treated)		Group2 (IS)		Group3 (HID)	
	Before	After	Before	After	Before	After
Hemoglobin (g/dL)	10.36± 0.87 ^{ab}	10.78± 1.52 ^c	10.55± 1.72 ^a	13.98± 2.76 ^a	10.20± 0.98 ^b	11.54± 1.88 ^b
RBCs (mm³)	3.21± 0.49 ^a	3.14± 0.42 ^b	3.02± 0.34 ^b	4.81± 0.50 ^a	3.13± 0.16 ^{ab}	3.58± 0.25 ^b
Hematocrit %	40.37± 2.94 ^a	40.95± 3.23 ^b	37.45± 2.56 ^b	49.13± 2.19 ^a	38.65± 2.25 ^b	42.55± 4.03 ^b
MCH(g/dL)	28.95± 2.04 ^a	28.10± 1.88 ^b	28.62± 1.48 ^a	30.32± 2.69 ^a	28.50± 1.52 ^a	29.77± 1.47 ^a
MCV (fL)	81.55± 4.16 ^a	82.04± 4.27 ^b	80.12± 5.13 ^a	87.60± 9.94 ^a	77.35± 5.21 ^b	81.75± 4.75 ^b
Platelets (mm³)	261.92± 56.68 ^a	266.67± 55.24 ^b	263.47± 59.43 ^a	285.50± 58.14 ^a	257.05± 45.98 ^a	268.10± 46.21 ^b

*Values are means ± SD

** The mean difference is significant at the 0.05 level.

Discussion

Obesity and iron deficiency (ID) are 2 of the most common nutritional disorders worldwide (Del-Giudice et al, 2009). ID, in developed countries, is the most common nutritional deficiency and has been linked to obesity in adults and children (Amatoet al., 2010). The association between iron status and obesity is one that should be explored further, as obesity and ID are diseases that continue to evolve globally, and both have significant public health implications (McClung and Karl, 2009). The global incidence of obesity has increased

dramatically over the past 50 years. Currently more than 1 billion people are thought to have a body mass index (BMI) of more than 30 kg/m², and the number is expected to increase dramatically over the next 30 years (**Chunget al., 2007**).

The global obesity epidemic reflects rapidly changing environments as societies develop, cultures integrate, food habits globalize, and urbanization and its corollary urban lifestyle replaces more active rural living. These shifts are often captured by the term nutrition transition, which refers to the interplay of economic, demographic, environmental and cultural changes in a society that are associated with shifting patterns of nutritional intake (**Mowafiet al., 2014**). Urban Egyptian women are disproportionately affected and have a higher prevalence of overweight/ obesity compared with most other developing nations. Egypt's observed overweight/obesity prevalence was (69.9%) far exceeded that which was expected (~35.0%) given (**Mendez et al., 2005**).

Iron plays a vital role in hemoglobin production and erythrocyte maturation. Two of the most common causes of anemia, IDA and the anemia of chronic inflammation, result from abnormalities in iron homeostasis (**Ausk and Ioannou, 2008**). Iron homeostasis in the body is controlled by a very complex mechanism, the main components of which are erythropoietic activity, hypoxia, iron stores, and inflammation (**Choudhry, 2010**).

However, iron may also function in the maintenance of body weight and composition, as a number of studies have suggested an association between iron status and obesity. The first such study, published in 1962 by Wenzel *et al.*, demonstrated significantly lower serum iron concentrations in obese adolescents in comparison to normal controls (**Wenzel et al., 1962**).

Menzieet al., (2008), found significantly lower levels of serum iron and transferrin saturation in obese people when compared to non-obese adult volunteers. They reported that the obese and the non-obese subjects did not differ in total daily iron consumption but that fat mass was a significant negative predictor of serum iron level.

There is an expanding body of literature demonstrating that obesity has an important role in modifying iron homeostasis. The association between excess weight, iron status, and iron absorption has been elegantly assessed in women and children from transition countries (**Zimmermann et al 2008**). Confirming previous studies, poorer iron status was notably more common in heavier participants. Independent of iron status, both BMI and inflammation (as measured by C-reactive protein) were negatively correlated with absorption of isotopically labeled iron from fortified foods. In addition, those with greater

adiposity were unable to improve their iron status by dietary means compared to lean controls. Although hepcidin was not measured, it was suggested by the authors that inflammation-induced hepcidin was likely causing a decrease in dietary iron absorption by diminishing the expression of Fpn located on the basolateral membrane of intestinal enterocytes thus impairing dietary repletion efforts.

Several studies have investigated the effect of diet-induced weight loss on iron status in both adults and children; however, results are conflicting. In adults, diet-induced weight loss was associated with maintenance or improvement in serum iron, TSAT, and hemoglobin (Weinsier *et al.*, 1983 and Rodríguez *et al.*, 2007).

However, Beard *et al.*, (1997), reported a significant decrease in TSAT after just 1 week of adherence to a very low- energy diet. Similarly, Kretschet *et al.*, (1998) reported a significant decrease in hemoglobin, hematocrit, and red blood cell count after a 15-week energy-restricted diet in a group of women with obesity.

Our study found that the mean of serum iron levels significantly lower among obese women; similar findings was recorded by Pinhas-Hamiet *et al.*, (2003) who reported that Iron-deficiency is common in overweight and obese children. A significantly greater proportion of obese than normal-weight children have iron-deficiency anemia. Also Chambers *et al.*, (2006) found a significant inverse association between central and total fat mass with serum iron concentrations in Hispanic women. Similar findings recorded by Ausk and Ioannou, (2008) who found that overweight and obesity were associated with changes in serum iron.

Results of this study shows significant of the mean value of weight which correlated with BMI of obese anemic women before and after treatment with daily dose of iron supplement 50mg and high iron diet. After three months of treatment with iron supplement the mean value of weight and BMI decreased significantly compared with control group and high iron diet group as shown in table (1). The results of our study indicated that the treatment with iron supplement of obese anemic women affects the waist and hip circumference, which decreased significantly compared with not treated patients and patients who taken high iron diet this effect reflect on waist to hip ratio. Our results found that thyroid hormones FT4 and TSH were in normal range in most cases that indicated that no intervention with the weight loss results (Table3).

Our results indicated significant improvement in hemoglobin, red blood cells hematocrit, MCV and MCH status in obese anemic women who treated with iron supplement (IS) compared with those who dependant of high iron diet only (Table4). The improvement of hemoglobin, RBCs and Hematocrit in patient who treated with (IS) is

related to the dose of ferrous bisglycinate 50mg/daily. The same results recorded by **Nils *et al.*, (2014)**, who indicated that ferrous bisglycinate in a low dose of 25 mg iron/day appears to be adequate to prevent IDA in more than 95% of Danish women during pregnancy and postpartum. Also **Aycicek A. (2015)**, reported that ferrous sulfate and ferrous fumarate plus zinc and vitamin C were well tolerated and were highly effective in correcting IDA in children

Enhancing in iron status in the case of a patient who intake high iron diet is related to nutrition education, diet modification (high Iron in the diet, intake foods rich in vitamin C after meals); The relationship between iron intake and iron status is complicated by variations in the efficiency of iron absorption, but a systematic review of randomised clinical trials show a positive time-dependent association between iron intake from supplemental iron and serum ferritin (**Casgrainet *al.*, 2012**).

Khoshnevisan *et al.*, (2013), found that during three months of nutrition education and diet modification, groups were significantly correlated to serum ferritin alteration. Frequency of fruit juice intake (rich in vitamin C) after meals (at least five times a week) can significantly increase serum ferritin within three months.

Our study showed association of overweight and obesity with iron deficiency. Our study suggests that the treatment of anemia is important for the treatment of overweight and obesity.

References

- Abu-Farha M., Tiss A., Abubaker J., Khadir A., Al Ghimlas F., Al-Khairi I., *et al.*, (2013)**: Epigenetic Factor HDAC4 as a Potential Target for Obesity. PLOS ONE 8(9): e75342: 1- 17.
- Amato A., Santoro N., Calabro P., Grandone A., Swinkels D.W., Perrone L. and delGiudice E.M. (2010)**: Effect of body mass index reduction on serum hepcidin levels and iron status in obese children. Int J Obes; 34:1772–1774.
- Ausk K.J., Ioannou G.N.(2008)**: Is obesity associated with anemia of chronic disease? A population-based study.obesity; 16:2356–2361.

- Aycicek A. (2015):** Ferrous Sulfate Versus Ferrous Fumarate Plus Zinc Sulfate and Vitamin C for Treatment of Iron Deficiency Anemia in Children. *Global J Hematology and Blood Transfusion*, 2:15-19.
- Batista F.M., Souza A.I., Miglioli T.C. and Santos M.C. (2008):** Anemia and obesity: A paradox of the nutritional transition in Brazil. *Cad SaudePublica*, 24 Suppl, 2: S247-57.
- Beard J., Borel M. and Peterson F.J. (1997):** Changes in iron status during weight loss with very-low-energy diets. *Am J Clin Nutr*; 66(1):104- 110.
- Beck-Peccoz P., Romelli P.B., Cattaneo M.G., Faglia G., White E.L., Barlow J.W. and Stockigt J.R. (1984):** Evaluation of free thyroxine methods in the presence of iodothyronine-binding autoantibodies. *J ClinEndocrinolMetab*; 58(4): 736-739.
- Bentley M.E. and Griffiths P.L. (2003):** The burden of anemia among women in India. *Eur J Clin Nutr*, 57(1):52-60.
- Casgrain A., Collings R., Harvey L.J., Hooper L. and Fairweather-Tait S.J.(2012):** Effect of iron intake on iron status: a systematic review and meta-analysis of randomized controlled trials. *Am. J. Clin. Nutr*; 96:768–780.
- Chambers E.C., Heshka S., Gallagher D., Wang J., Pi-Sunyer F.X. and Pierson R.N. (2006):** Serum iron and body fat distribution in a multiethnic cohort of adults living in New York City. *J Am Diet Assoc*; 106(5):680-684.
- Choudhry V.P. (2010):**Hepcidin and its role in iron metabolism. *Indian J Pediatr*; 77:787–789.
- Chung B., Matak P., McKie A.T. and Sharp P. (2007):**Leptin increases the expression of the iron regulatory hormone hepcidin in HuH7 human hepatoma cells. *J Nutr*; 137:2366–2370.
- Del-Giudice E.M., Santoro N., Amato A., Brienza C., Calabrò P., et al, (2009):**Hepcidin in obese children as a potential mediator of the association between obesity and iron deficiency. *J ClinEndocrinolMetab*; 94:5102–5107.

- Flegal K.M., Graubard B.I., Williamson D.F. and Gail M.H. (2007):** Causespecific excess deaths associated with underweight, overweight, and obesity. *JAMA*; 298:2028–2037.
- Fossati P. and Prencipe L. (1982):** Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. *Clin.Chem* 28(10): 2077-2080.
- Friedewald W. T., Levy R. T. and Fredickson D. S. (1972):** Estimation of the concentration of LDL-cholesterol without use of plasma ultracentrifuge *Clin. Chem.* 18: 499 – 520.
- Grove T.H. (1979):** Effect of reagent pH on Determination of HDL Cholesterol by precipitation with Sodium Phosphotungstate-magnesium *ClinChem* 25:560-561.
- Hanafi M.I., Abdallah A.R. and Zaky A. (2013):** Study of hemoglobin level and body mass index among preparatory year female students at Taibah University, Kingdom of Saudi Arabia. *Journal of Taibah University Medical Sciences.* 8(3):160-166.
- Khoshnevisan F., Kimiagar M., Kalantaree N., Valaee N. and Shaheedee N. (2013):**Effect of Nutrition Education and Diet Modification in Iron Depleted Preschool Children in Nurseries in Tehran: a Pilot Study. *Int J Vitamin and Nutrition Research.*264-268.
- Kretsch M.J., Fong A.K., Green M.W. and Johnson H.L.(1998):** Cognitive function, iron status, and hemoglobin concentration in obese dieting women. *Eur J ClinNutr*; 52(7):512-518.
- McClung J.P. and Karl J.P.(2009):** Iron deficiency and obesity: the contribution of inflammation and diminished iron absorption. *Nutr Rev*; 67:100–104.
- Mendez M.A., Monteiro C.A. and Popkin B.M. (2005):** Overweight exceeds underweight among women in most developing countries. *Am J ClinNutr*; 81(3):714–21.
- Menzie CM, Yanoff LB, Denkinger BI, McHugh T, Sebring NG, Calis KA, Yanovski JA. (2008):** Obesity-related hypoferrremia is not explained by differences in reported intake of heme and

nonheme iron or intake of dietary factors that can affect iron absorption. *J Am Diet Assoc*; 108:145–148.

- Mowafi, M., Khadr, Z., Kawachi, I., Subramanian, S.V., Hill, A., Bennett, G.G. (2014):** Socioeconomic status and obesity in Cairo, Egypt: A heavy burden for all. *J Epidemiol Glob Health*.;4:13–21.
- Naito H.K. (1984):** Cholesterol. Kaplan *Aet al.*, ClinChem The C.V. Mosby Co. St Louis. Toronto. Princeton; 1194-11206 and 437.
- Nead K.G., Halterman J.S., Auinger P., Weitzman M. and Kaczorowski J.M. (2004):** Overweight children and adolescents: A risk group for iron deficiency. *Pediatr*, 114(1): 104-108.
- Nils M., Lisbeth J., Pernille D., Palle L.P. and Lise G. L. (2014):** Ferrous bisglycinate 25 mg iron is as effective as ferrous sulfate 50 mg iron in the prophylaxis of iron deficiency and anemia during pregnancy in a randomized trial. *J Perinatal Medicine*. 42: 197–206.
- Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J. and Flegal KM.(2006):** Prevalence of overweight and obesity in the United States, 1999–2004. *JAMA*.; 295:1549–1555.
- Pinhas-Hamiel O., Newfield R.S., Koren I., Arnon A., Lilos P. and Phillip M. (2003):** Greater prevalence of iron deficiency in overweight and obese children and adolescents. *Int J of Obe.* (27): 416–418.
- Rodríguez E., López-Sobaler A.M., Andrés P., Aparicio A., Navia B. and Ortega R.M.(2007):** Modification of iron status in young overweight/ mildly obese women by two dietary interventions designed to achieve weight loss. *Ann NutrMetab*; 51(4):367-373.
- Sultan A.H. (2007):** Anemia among female college students attending the University of Sharjah, UAE: prevalence and classification; *J Egypt Public Health Assoc*. 82:261-271.
- Uotila M., Ruoslahti E. and Engvall E. (1981):** *J. Immunol. Methods*, 42:11-15.
- Wang Y. and Lobstein T.(2006):** Worldwide trends in childhood overweight and obesity. *Int J Pediatric Obes*; 1:11–25.

- Weinsier R.L., Bacon J.A. and Birch R.(1983):** Time-calorie displacement diet for weight control: A prospective evaluation of its adequacy for maintaining normal nutritional status. *Int J Obes*; 7(6):539-548.
- Wenzel B.J., Stults H.B. and Mayer J. (1962):**Hypoferraemia in obese adolescents. *Lancet*, 2:327–328.
- WHO, (2000):** Obesity: preventing and managing the global epidemic. Report of a WHO Consultation on Obesity; World Health Organ Tech Rep Ser. 894: 1-253, 2000.
- WHO, (2006):** Obesity and Overweight. Fact sheet No. 311.2006; Available at: <http://www.who.int/mediacentre/factsheets/fs311/en/index.html>.
- Yanoff L.B., Menzie C.M., Denkinger B. et al. (2007):** Inflammation and iron deficiency in the hypoferraemia of obesity. *Int. J. Obes. (Lond)*; 31:1412–1419.
- Zimmermann M.B., Zeder C., Muthayya S., Winichagoon P., Chaouki N., Aeberli I. andHurrell R.F. (2008):** Adiposity in women and children from transition countries predicts decreased iron absorption, iron deficiency and a reduced response to iron fortification. *International Journal of Obesity* 32:1098–104.